Global Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,153.4 Million in 2022 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing launches of new antiplatelet drugs is expected to drive the global antiplatelet drugs market growth over the forecast period. For instance, in November 2020, AstraZeneca plc, a pharmaceutical and biotechnology company, launched new product Brilinta, which contained a new drug for antiplatelet namely ticagrelor had been approved by the U.S. Food and Drug Administration, to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack (TIA). The approval by the U.S. Food and Drug Administration (FDA) was based on positive results from the THALES Phase III trial, which showed that aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischaemic stroke or TIA.
Global Antiplatelet Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global antiplatelet drugs market, owing to its possible association with the COVID-19 infection. For instance, in December 2020, according to the National Center for Biotechnology Information, the proportion of COVID-19 patients with major cardiovascular risk factors who developed acute arterial thrombosis is higher than that of their non-COVID-19 counterparts. Such finding hinted at the possibility that thromboinflammation played a greater role for the development of arterial thrombosis in COVID-19 patients than traditional cardiovascular risk factors. In addition, the mortality rate of COVID-19 patients with arterial thrombosis was high (44.7%), which indicates a poor prognosis. Therefore, doctors propose routine antiplatelet therapy (low-dose aspirin, clopidogrel, ticagrelor, prasugrel, ticlopidine, and dipyridamole) for arterial thromboprophylaxis in COVID-19 patients who are deemed at heightened risk for the development of acute arterial thrombosis. Low-dose aspirin (75–150mg/d) is sufficient to irreversibly acetylate Ser 530 of COX-1, thus preferentially inhibiting platelet generation of thromboxane A2, and interfering with the formation of arterial thrombus. On the other hand, for P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel, and ticlopidine), either the parent drug or the active metabolite blocks the P2Y12 (adenosine diphosphate receptor) component of adenosine diphosphate receptors on the platelet surface, which prevents activation of the glycoprotein IIb/IIIa receptor complex, thereby reducing platelet aggregation and subsequent arterial thrombus formation.
Global Antiplatelet Drugs Market: Key Developments
In January 2022, Sanofi-aventisand Bristol-Myers Squibb Company, a pharmaceutical company announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX(R) (clopidogrel bisulfate) to reduce the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death in patients with acute ST-segment elevation myocardial infarction (STEMI). STEMI is a severe acute heart attack in which a coronary artery is generally blocked completely. These blockages are caused by clot formation in the arteries, a life-threatening complication of an underlying disease known as atherothrombosis.
Browse 31 Market Data Tables and 33 Figures spread through 185 Pages and in-depth TOC on “Global Antiplatelet Drugs Market ”- Forecast to 2030, Global Antiplatelet Drugs Market , by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/antiplatelet-drugs-market-2190
Key Takeaways of the Global Antiplatelet Drugs Market:
- Global antiplatelet drugs market is expected to exhibit a CAGR of 7.8% during the forecast period due to the increasing launches of new products. For instance, in October 2017, Panacea Biotec, a pharmaceutical company, got the U.S. Food & Drug Administration (U.S.FDA) approval for Prasugrel 5mg and 10mg tablets. According to an official release, the product has been launched in market by Apotex Corp., the largest Canada-based pharmaceutical company which is the exclusive sales and distribution partner for this product in the US.
- Among regions, North America is estimated to account for the largest market share in the global antiplatelet drugs market over the forecast period, owing to the increasing prevalence of cardiac disorder in that region. For instance, on January 26 2022, according to the American Heart Association, in the Cardiovascular Lifetime Risk Pooling Project among 30 447 participants from 7 US cohort studies, among individuals ≥60 years of age with low Chronic Venous insufficiency, the 35-years old people with higher risk of Cardiovascular disease was highest in White males (65.5%), followed by White females (57.1%), Black females (51.9%), and Black males (48.4%). These estimated risks accounted for competing risks of death caused by non-CVD causes. The large number of individuals in the U.S. who contracted severe illness because of coronavirus disease 2019 (COVID-19) resulted in a huge mortality toll. As of March 2021, the cumulative number of COVID-19 deaths in the U.S. was ≈545 000, which equates to ≈166 cases per 100 000 people, with higher rates of deaths occurring among U.S. counties with metropolitan areas (≈185 deaths per 100 000), with a high percentage (>45.5%) of the population that is non-Hispanic (NH) Black (≈200 deaths per 100 000), with a high proportion (>37%) of the population that is Hispanic (≈219 deaths per 100 000), or with a high percentage (>17.3%) of the population that are living in poverty (≈211 deaths per 100 000 people).
- Major players operating in the global antiplatelet drugs market include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
